Plus   Neg

Astellas Pharma Buys Xyphos Biosciences To Strengthen Immuno-oncology Pipeline

Tokyo, Japan-based Astellas Pharma Inc. (ALPMY) announced the acquisition of South San Francisco, CA-based privately held development-stage biotechnology company Xyphos Biosciences, Inc.

This total transaction is valued at $665 million, including $120 million paid upon closing of the acquisition and potential future development milestone payments. Xyphos became a wholly owned subsidiary of Astellas.

Astellas expects to gain Xyphos' novel and proprietary ACCEL or Advanced Cellular Control through Engineered Ligands technology platform, as well as adds talent to accelerate next-generation cancer immunotherapy.

Xyphos' first convertibleCAR-T cell product candidate is in preclinical development and scheduled to be tested in a first-in-human clinical study in 2021.

Astellas expects an limited impact from this transaction on its financial results in the fiscal year ending March 31, 2020.

Kenji Yasukawa, President and CEO, Astellas, stated, "The innovative technology in development at Xyphos fits perfectly in advancing our immuno-oncology strategy to create and deliver value for patients."

ALPMY closed Thursday's session at $17.11.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement. Gap Inc. partnered with fashion resale platform thredUP to facilitate the exchange of secondhand cloths. The retailer in a blog post said its customers can bring secondhand clothes in exchange for shopping credit that can be redeemed at Gap, Banana Republic, Athleta, or Janie and Jack. Customers who redeem their credits at Gap brands will receive an additional 15 percent payout bonus. Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference. For fiscal 2020, the company continues to project...
Follow RTT